Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid
© 2018 Newlands Press. Aim: Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit® (ED) polymers have improved formulation stability of antidiabetic drugs. The aim of the study is to test if DCA and ED encapsulation will optimize the release and stability of the potential an...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2018
|
| Online Access: | http://hdl.handle.net/20.500.11937/71355 |
| _version_ | 1848762457975160832 |
|---|---|
| author | Mooranian, A. Zamani, N. Mikov, M. Golocorbin-Kon, S. Stojanovic, G. Arfuso, Frank Al-Salami, Hani |
| author_facet | Mooranian, A. Zamani, N. Mikov, M. Golocorbin-Kon, S. Stojanovic, G. Arfuso, Frank Al-Salami, Hani |
| author_sort | Mooranian, A. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © 2018 Newlands Press. Aim: Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit® (ED) polymers have improved formulation stability of antidiabetic drugs. The aim of the study is to test if DCA and ED encapsulation will optimize the release and stability of the potential antidiabetic drug probucol (PB). Materials & methods: The PB formulations were prepared using ED polymers and DCA, and formulations were analyzed for their rheological and biological properties. Results: Rheological properties and size distribution were similar among all groups. ß-cell survival and biological activities were best with NM30D microcapsules. The inflammatory profile and oxidative stress effects of microcapsules remained similar among all groups. Conclusion: ED NM30D and DCA incorporation can exert positive and stabilizing effects on PB oral microcapsules. |
| first_indexed | 2025-11-14T10:47:53Z |
| format | Journal Article |
| id | curtin-20.500.11937-71355 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:47:53Z |
| publishDate | 2018 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-713552019-04-08T04:04:03Z Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid Mooranian, A. Zamani, N. Mikov, M. Golocorbin-Kon, S. Stojanovic, G. Arfuso, Frank Al-Salami, Hani © 2018 Newlands Press. Aim: Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit® (ED) polymers have improved formulation stability of antidiabetic drugs. The aim of the study is to test if DCA and ED encapsulation will optimize the release and stability of the potential antidiabetic drug probucol (PB). Materials & methods: The PB formulations were prepared using ED polymers and DCA, and formulations were analyzed for their rheological and biological properties. Results: Rheological properties and size distribution were similar among all groups. ß-cell survival and biological activities were best with NM30D microcapsules. The inflammatory profile and oxidative stress effects of microcapsules remained similar among all groups. Conclusion: ED NM30D and DCA incorporation can exert positive and stabilizing effects on PB oral microcapsules. 2018 Journal Article http://hdl.handle.net/20.500.11937/71355 10.4155/tde-2018-0036 restricted |
| spellingShingle | Mooranian, A. Zamani, N. Mikov, M. Golocorbin-Kon, S. Stojanovic, G. Arfuso, Frank Al-Salami, Hani Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid |
| title | Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid |
| title_full | Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid |
| title_fullStr | Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid |
| title_full_unstemmed | Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid |
| title_short | Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid |
| title_sort | eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid |
| url | http://hdl.handle.net/20.500.11937/71355 |